Research News for June 2012
-
FDA Advisory Panel Approves MarginProbe System
An FDA expert panel voted to approve the MarginProbe system - a device that helps surgeons decide if all the cancer tissue has been removed during lumpectomy.
-
Experimental Vaccine May Help Reduce Recurrence Risk of HER2-Positive Disease
A new study has found that an experimental vaccine targeting HER2-positive breast cancer cells lowered the risk of the cancer coming back in women diagnosed with HER2-positive, early-stage breast cancer.
-
Perjeta Improves Overall Survival in HER2-Positive, Metastatic Disease
More results from the CLEOPATRA study show that women who got Perjeta, Herceptin, and Taxotere had better overall survival than women who got only Herceptin and Taxotere.
-
Another Study Suggests Night Work Raises Risk
A French study has found that women who worked the night shift were 35% more likely to be diagnosed with breast cancer compared to women who never worked night shifts.
-
AMA Updates Mammogram Policy, Says Screening Should Start at 40
The American Medical Association's new policy says that all women should be eligible for screening mammograms starting at age 40 and that all insurance plans should cover the cost of the screening.
-
Breast Cancer’s Hormone Receptor and HER2 Status Can Change After Diagnosis
The characteristics of a breast cancer -- including hormone receptor status and HER2 status -- can change over time. These changes may happen because the cancer cells change themselves or because treat...
-
Diabetes Medicine Linked to Lower Risk
A large study has found that diabetic women taking the medicine metformin had a lower-than-average-risk of breast cancer.
-
Circulating Tumor Cells Linked to Worse Prognosis in Early-Stage Disease
A study has found that circulating tumor cells in the bloodstream are linked to worse prognosis in people diagnosed with early-stage breast cancer.
-
Ginseng Helps Ease Treatment-Related Fatigue
A study has found ginseng capsules helped ease the fatigue that many people have during and after cancer treatment.
-
FDA Approves Perjeta for Metastatic, HER2-Positive Disease
The FDA has approved using Perjeta (chemical name: pertuzumab) in combination with Herceptin and Taxotere to treat HER2-positive, metastatic breast cancer that hasn't been treated with either Herceptin or chemotherapy yet.
